NasdaqGS:RPRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,058	933	3,004	2,889	5
12/31/2025	2,839	908	2,698	2,616	5
12/31/2024	2,663	634	2,585	2,467	5
6/30/2024	2,238	673	401	2,669	N/A
3/31/2024	2,239	799	1,019	2,619	N/A
12/31/2023	2,355	1,135	872	2,988	N/A
9/30/2023	2,324	184	1,422	2,785	N/A
6/30/2023	2,361	255	522	2,750	N/A
3/31/2023	2,359	332	374	2,718	N/A
12/31/2022	2,237	43	402	2,144	N/A
9/30/2022	2,247	507	401	2,064	N/A
6/30/2022	2,259	466	312	1,995	N/A
3/31/2022	2,278	602	263	1,952	N/A
12/31/2021	2,289	620	-174	2,018	N/A
9/30/2021	2,286	783	-732	2,093	N/A
6/30/2021	2,239	972	-159	2,132	N/A
3/31/2021	2,195	493	-496	2,090	N/A
12/31/2020	2,122	495	-148	2,035	N/A
9/30/2020	2,008	1,745	104	1,947	N/A
6/30/2020	1,934	1,863	793	1,858	N/A
3/31/2020	1,880	2,052	1,093	1,705	N/A
12/31/2019	1,814	2,349	-54	1,667	N/A
12/31/2018	1,795	1,378	1,349	1,618	N/A
12/31/2017	1,598	1,210	N/A	1,418	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RPRXの予測収益成長率 (年間12.5% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: RPRXの収益 ( 12.5% ) US市場 ( 14.8% ) よりも低い成長が予測されています。

高成長収益: RPRXの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: RPRXの収益 ( 8.4% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: RPRXの収益 ( 8.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RPRXの自己資本利益率は、3年後には低くなると予測されています ( 13.9 %)。

Royalty Pharma 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 33%

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Consensus EPS estimates increase by 79%

Consensus EPS estimates increase by 68%

Consensus EPS estimates increase by 94%

Recent updates

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Consensus EPS estimates fall by 33%

Royalty Pharma: Busy Putting Capital To Work

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of US$0.21 per share

Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

First quarter dividend of US$0.21 announced

Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024

Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Upcoming dividend of US$0.21 per share

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Fourth quarter dividend of US$0.21 announced

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 79%

Royalty Pharma: Solid Operational Performance

Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)

Upcoming dividend of US$0.21 per share at 2.9% yield

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Consensus EPS estimates increase by 68%

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Consensus EPS estimates increase by 94%

Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)

Upcoming dividend of US$0.20 per share at 2.9% yield

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 15%

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock

Insider notifies of intention to sell stock

Director notifies of intention to sell stock

Founder recently bought US$7.7m worth of stock

Consensus EPS estimates increase by 243%

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of US$0.20 per share at 2.4% yield

First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)

Consensus EPS estimates increase by 46%

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Director recently sold US$5.1m worth of stock

Insider recently sold US$932k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations